WO1999027952A1 - Produit anti-hypoxique et anti-ischemique - Google Patents
Produit anti-hypoxique et anti-ischemique Download PDFInfo
- Publication number
- WO1999027952A1 WO1999027952A1 PCT/RU1997/000383 RU9700383W WO9927952A1 WO 1999027952 A1 WO1999027952 A1 WO 1999027952A1 RU 9700383 W RU9700383 W RU 9700383W WO 9927952 A1 WO9927952 A1 WO 9927952A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hypoxic
- tissues
- drug
- ischemic
- hypoxia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- Antigens and anti-ischemic products The area of technology.
- the anti-ischemic antihypoxic drug Energostim is known (Patent No. 2035907).
- the indicated metabolic product contains nitinamide adenine dinucleotide ( ⁇ D 0.5 mg), C (10 mg), and is metabolite-free (80 mg).
- Inosine a component of the energy-stimulating substance, stimulates the synthesis of adenyl nucleotides and also enhances the synthesis, which also facilitates the synthesis of ⁇ . Otherwise, it increases the immune properties of the organism.
- P ⁇ s ⁇ avlennaya task ⁇ eshena ⁇ u ⁇ em d ⁇ lni ⁇ eln ⁇ g ⁇ v ⁇ lyucheniya in s ⁇ s ⁇ av an ⁇ igi ⁇ - siches ⁇ g ⁇ and an ⁇ iishemiches ⁇ g ⁇ s ⁇ eds ⁇ va on ⁇ sn ⁇ ve me ⁇ ab ⁇ liches ⁇ y s ⁇ s ⁇ avlyayuschey (Ene ⁇ g ⁇ s ⁇ ima) ⁇ e ⁇ men ⁇ v: ⁇ lavinadenindinu ⁇ le ⁇ id ( ⁇ D, ⁇ lavinm ⁇ n ⁇ nu ⁇ le- ⁇ nda or i ⁇ ⁇ edshes ⁇ venni ⁇ a ⁇ ib ⁇ lavina, vzaim ⁇ ev ⁇ aschayushi ⁇ sya in ⁇ ganizme, flavins), and the component of Ou (murderer), in the following case of the components of the r.h .:
- the commercial component is 65.5 - 98.3.
- ⁇ D and the product of its degradation ⁇ performs an important specific role on different stages of the cycle of the process and the process of the process of elec- trons.
- Part 010 is a highly portable electronic power supply for flavin circuits.
- component 010 takes advantage of a selective function, taking away the effects of permanent equivalents, which can result in different substances. Consequently, ⁇ D is responsible for the availability of viable equivalents for both CS Sprint and ⁇ ⁇ -dependent substances, and that urea is dependent on dehydrogen dehydrogenase and non-destructive substances. With this, the killer is the only transcendental chain that is not unique, not unrelated to protein. This explains its easy washability from the membranes.
- EXAMPLE 1 The study was conducted on white, non-hazardous potatoes, weighing 200-250 g, were divided into low-sensitivity and fast-to-use cases. P ⁇ iv ⁇ gi ⁇ siches ⁇ uyu a ⁇ ivn ⁇ s ⁇ ⁇ m- bini ⁇ vann ⁇ g ⁇ s ⁇ eds ⁇ va, eg ⁇ ⁇ i ⁇ a and ing ⁇ edien ⁇ v and ⁇ a ⁇ zhe ⁇ yad e ⁇ al ⁇ nny ⁇ an ⁇ i- gi ⁇ san ⁇ v studied on m ⁇ deli ⁇ s ⁇ y gi ⁇ ba ⁇ iches ⁇ y gi ⁇ sii, s ⁇ che ⁇ ayuscheysya with gi- ⁇ e ⁇ a ⁇ niey - zhiv ⁇ ny ⁇ ⁇ dnimali on vys ⁇ u 11.5 ⁇ ys s ⁇ s ⁇ s ⁇ y ⁇ m 50 m / s in zam ⁇ nu- ⁇ m
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU61260/98A AU6126098A (en) | 1997-11-28 | 1997-11-28 | Anti-hypoxic and anti-ischemic drug |
EP97954965A EP1034791A1 (en) | 1997-11-28 | 1997-11-28 | Anti-hypoxic and anti-ischemic drug |
HU0400931A HUP0400931A2 (hu) | 1997-11-28 | 1997-11-28 | Hypoxia és ischaemia elleni gyógyszer |
PCT/RU1997/000383 WO1999027952A1 (fr) | 1997-11-28 | 1997-11-28 | Produit anti-hypoxique et anti-ischemique |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU1997/000383 WO1999027952A1 (fr) | 1997-11-28 | 1997-11-28 | Produit anti-hypoxique et anti-ischemique |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999027952A1 true WO1999027952A1 (fr) | 1999-06-10 |
Family
ID=20130172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1997/000383 WO1999027952A1 (fr) | 1997-11-28 | 1997-11-28 | Produit anti-hypoxique et anti-ischemique |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1034791A1 (ru) |
AU (1) | AU6126098A (ru) |
HU (1) | HUP0400931A2 (ru) |
WO (1) | WO1999027952A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0114701A (pt) | 2000-10-26 | 2003-11-18 | Fournier Lab Ireland Ltd | Combinação de fenofibrato e coenzima q 10 para tratamento de disfunção endotelial |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2423222A1 (fr) * | 1978-04-22 | 1979-11-16 | Wuelfing Johann | Composition pharmaceutique contenant un derive de xanthine |
EP0173039A2 (en) * | 1984-07-19 | 1986-03-05 | BEECHAM - WUELFING GmbH & Co. KG | Use of xanthine and thioxanthine derivatives for the preparation of medicaments |
SU1491515A1 (ru) * | 1987-03-23 | 1989-07-07 | Киевский Медицинский Институт Им.Акад.А.А.Богомольца | Способ лечени неревматических миокардитов |
RU2006224C1 (ru) * | 1985-05-06 | 1994-01-30 | Украинский научно-исследовательский институт геронтологии АМН Украины | Мембраностабилизирующее и антиоксидантное лекарственное средство "рикавит" |
SU1417242A1 (ru) * | 1985-10-28 | 1995-10-27 | Г.М. Яковлев | Способ получения вещества, восстанавливающего функцию миокарда |
-
1997
- 1997-11-28 HU HU0400931A patent/HUP0400931A2/hu unknown
- 1997-11-28 WO PCT/RU1997/000383 patent/WO1999027952A1/ru not_active Application Discontinuation
- 1997-11-28 AU AU61260/98A patent/AU6126098A/en not_active Abandoned
- 1997-11-28 EP EP97954965A patent/EP1034791A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2423222A1 (fr) * | 1978-04-22 | 1979-11-16 | Wuelfing Johann | Composition pharmaceutique contenant un derive de xanthine |
EP0173039A2 (en) * | 1984-07-19 | 1986-03-05 | BEECHAM - WUELFING GmbH & Co. KG | Use of xanthine and thioxanthine derivatives for the preparation of medicaments |
RU2006224C1 (ru) * | 1985-05-06 | 1994-01-30 | Украинский научно-исследовательский институт геронтологии АМН Украины | Мембраностабилизирующее и антиоксидантное лекарственное средство "рикавит" |
SU1417242A1 (ru) * | 1985-10-28 | 1995-10-27 | Г.М. Яковлев | Способ получения вещества, восстанавливающего функцию миокарда |
SU1491515A1 (ru) * | 1987-03-23 | 1989-07-07 | Киевский Медицинский Институт Им.Акад.А.А.Богомольца | Способ лечени неревматических миокардитов |
Also Published As
Publication number | Publication date |
---|---|
AU6126098A (en) | 1999-06-16 |
HUP0400931A2 (hu) | 2004-07-28 |
EP1034791A1 (en) | 2000-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leung et al. | Thymopentin therapy reduces the clinical severity of atopic dermatitis | |
Bertino et al. | Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil | |
Rees et al. | Aminopterin for psoriasis | |
JP5005143B2 (ja) | 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用 | |
Safadi et al. | Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication | |
McDonald et al. | Treatment of Mycosis Fungoides Lymphoma: Effectiveness of Infusions of Methotrexate Followed by Oral Citrovorum Factor¹, 2 | |
WO1995017902A1 (fr) | Utilisation d'une souche du champignon fusarium comme producteur de substances et preparation a base celle-ci presentant, des proprietes, adaptogeniques et immunomodulatrices | |
US3574857A (en) | Antilipidemic methods using glutamic acid,threonine and proline | |
WO1999027952A1 (fr) | Produit anti-hypoxique et anti-ischemique | |
Tripathy | Relapse in tuberculosis | |
Erard et al. | Regulation of contact sensitivity to DNFB in the mouse: effects of adult thymectomy and thymic factor | |
Thong et al. | Immunopotentiation by pyrimethamine in the mouse. | |
Dray et al. | Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy | |
JP3520084B2 (ja) | 多発性硬化症を含めた炎症の治療におけるペプチドt及びその関連ペプチド類 | |
Gasser et al. | Roxithromycin in the treatment of Lyme disease-update and perspectives | |
Parrott et al. | The Thymus and Immnity [Abridged] The Immunological Status of Thymectomized Animals—A Survey | |
EP0290817B1 (en) | A use of oxetanocin for inhibiting hiv | |
Haley et al. | Comparison of Strophanthin-K and Tryptamine-Strophanthidin after Intra-ventricular Injection in Unanesthetized Dogs. | |
EP0372676A1 (en) | Therapeutic preparation and method | |
Goldin et al. | Augmentation of Therapeutic Efficacy of 3′, 5′-Dichloroamethopterin against an Antifolic-resistant Variant of Leukemia (L1210-M46R) in Mice | |
Lubong et al. | Culturing of HIV-1-specific cytotoxic T lymphocytes with interleukin-7 and interleukin-15 | |
Koshimura et al. | Enhancement of Antileukemic Effect in the Combination of 5-Fluorouracil and OK-432 1, 2, 3 | |
ZISKIND et al. | The Use of the Iso-Nicotinic Acid Hydrazides in the Treatment of Tuberculosis | |
JP2000514066A (ja) | 抗ウイルス性抗腫瘍剤としてのインターロイキン―8 | |
Tibell et al. | Cyclosporine A in fat emulsion carrier: immunosuppressive effect in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997954965 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-451/00 Country of ref document: YU |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954965 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997954965 Country of ref document: EP |